| Literature DB >> 28415653 |
Xiao-Dong Li1, Hao Zi1, Cheng Fang2, Xian-Tao Zeng1,2,3.
Abstract
The hypoxia inducible factor 1-alpha (HIF1A) gene has been suggested to play a critical role in cancer progression, and the relationship between HIF1A rs11549465 polymorphism and risk of prostate cancer has been investigated in previous studies. Nevertheless, conflicting results have been obtained. Hence, we reevaluated this issue by means of this meta-analysis, with the purpose of providing more precise conclusion on this issue. The electronic databases of PubMed, EMBASE and Chinese National Knowledge Infrastructure (CNKI) as well as other sources were searched for relevant reports concerning on the role of HIF1A rs11549465 polymorphism in the occurrence of prostate cancer. The strength of the relationship was determined by calculating odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs). Besides, subgroup analyses by ethnicity and source of control were further performed to examine this relationship. All statistical analyses were performed using STATA software 12.0. Although HIF1A rs11549465 polymorphism showed a tendency of increasing the risk of prostate cancer, no statistical significance was detected under any genetic models. Similar results were also revealed in subgroup analyses on the basis of ethnicity and control source. Our findings indicate that HIF1A rs11549465 polymorphism may not independently play a significant role in the occurrence of prostate cancer.Entities:
Keywords: HIF1A; polymorphism; prostate cancer; risk; susceptibility
Mesh:
Substances:
Year: 2017 PMID: 28415653 PMCID: PMC5546530 DOI: 10.18632/oncotarget.16489
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow diagram of selecting eligible studies for the meta-analysis
Major characteristics of all studies included in the present study
| First author, year | Country | Ethnicity | Control source | Sample size | Case | Control | HWE | Genotyping method | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case/control | CC | CT | TT | C | T | CC | CT | TT | C | T | ||||||
| Li, 2007 | USA | Caucasian | PB | 1041/1234 | 818 | 209 | 14 | 1845 | 237 | 995 | 221 | 18 | 2211 | 257 | 0.159 | PCR-RFLP |
| Orr-Urtreger, 2007 | Israel | Caucasian | PB | 251/200 | 170 | 72 | 9 | 412 | 90 | 147 | 51 | 2 | 345 | 55 | 0.288 | PCR-RFLP |
| Orr-Urtreger, 2007 | Israel | Caucasian | PB | 151/100 | 117 | 27 | 7 | 261 | 41 | 70 | 29 | 1 | 169 | 31 | 0.284 | PCR-RFLP |
| Jacobs, 2008 | USA | Caucasian | PB | 1420/1450 | 1156 | 252 | 12 | 2564 | 276 | 1138 | 284 | 28 | 2560 | 340 | 0.041 | MassARRAY |
| Foley, 2009 | Ireland | Caucasian | PB | 95/188 | 65 | 30 | 0 | 160 | 30 | 175 | 13 | 0 | 363 | 13 | 0.623 | Sequencing |
| Li, 2012 | China | Asian | HB | 662/716 | 612 | 48 | 2 | 1272 | 52 | 659 | 57 | 0 | 1375 | 57 | 0.267 | TaqManSNP |
| Fraga, 2014 | Portugal | Caucasian | HB | 754/736 | 579 | 164 | 11 | 1322 | 186 | 566 | 156 | 14 | 1288 | 184 | 0.399 | TaqManSNP |
| Chau, 2005 | USA | Mixed | PB | 196/196 | 161 | 29 | 6 | 351 | 41 | 179 | 14 | 3 | 372 | 20 | 0.0002 | Sequencing |
PB, Population-based; HB, Hospital-based; HWE, Hardy-Weinberg Equilibrium; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism.
HIF1A rs11549465 polymorphism and risk of prostate cancer
| Genetic contrast | Odds ratio (95% confidence interval) / | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Caucasian | Other-ethnicity | Population-based | Hospital-based | Total | ||||||
| TT versus CC | 0.98 (0.49, 1.97) | 0.040 | 2.60 (0.73, 9.28) | 0.603 | 1.30 (0.55, 3.07) | 0.018 | 0.92 (0.44, 1.95) | 0.221 | 1.17 (0.61, 2.23) | 0.037 |
| TT + CT versus CC | 1.20 (0.86, 1.66) | 0.000 | 1.42 (0.60, 3.38) | 0.018 | 1.40 (0.93, 2.10) | 0.000 | 0.99 (0.81, 1.21) | 0.789 | 1.23 (0.93, 1.64) | 0.000 |
| TT versus CC+CT | 0.98 (0.49, 1.96) | 0.042 | 2.51 (0.72, 8.80) | 0.563 | 1.28 (0.55, 2.96) | 0.022 | 0.92 (0.44, 1.93) | 0.218 | 1.15 (0.61, 2.16) | 0.044 |
| T versus C | 1.19 (0.89, 1.59) | 0.000 | 1.43 (0.66, 3.09) | 0.022 | 1.39 (0.96, 2.01) | 0.000 | 0.99 (0.82, 1.19) | 0.995 | 1.23 (0.95, 1.60) | 0.000 |
| CT versus CC | 1.18 (0.85, 1.64) | 0.000 | 1.39 (0.56, 3.45) | 0.019 | 1.35 (0.90, 2.05) | 0.000 | 0.99 (0.80, 1.23) | 0.602 | 1.21 (0.90, 1.61) | 0.000 |
Figure 2Forest plot for the correlation between HIF1A rs11549465 polymorphism and prostate cancer susceptibility under TT versus CC genetic model. The squares and horizontal lines correspond to the study-specific OR and 95% CI
The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
Figure 3Begg's funnel plot of publication bias for HIF1A rs11549465 polymorphism
Each point represents a separate study for the indicated association.